Insulin Lispro Sanofi

Insulin lispro, the active ingredient in Insulin Lispro Sanofi, is a rapid‑acting insulin analog presented as a sterile solution for subcutaneous use. It is indicated for the management of blood glucose in adults and children with type 1 or type 2 diabetes mellitus. GNH USA supplies Insulin Lispro Sanofi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Insulin Lispro Sanofi is a rapid‑acting insulin analog used to control post‑prandial glucose levels in diabetes mellitus. - Type 1 diabetes mellitus: provides rapid glucose lowering after meals to achieve target glycaemic control. - Type 2 diabetes mellitus: complements basal insulin or oral agents for mealtime glucose management. - Insulin pump therapy: serves as the rapid‑acting component in continuous subcutaneous insulin infusion systems.

Insulin Lispro Sanofi may cause a range of adverse reactions.

Common Side Effects: - Hypoglycaemia: low blood glucose levels, often presenting with sweating, tremor, or confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight associated with improved glycaemic control. - Lipodystrophy: localized changes in subcutaneous fat at injection sites.

Serious or Rare Side Effects: - Severe hypoglycaemia: neuroglycopenic symptoms requiring immediate assistance. - Allergic reactions: urticaria, angio‑edema, or anaphylaxis. - Insulin edema: peripheral swelling due to fluid retention. - Hypokalemia: low serum potassium, especially with high insulin doses.

When using Insulin Lispro Sanofi, consider the following precautions. - Hypoglycaemia risk: monitor blood glucose frequently, especially when initiating therapy or adjusting doses. - Renal impairment: reduce dose and monitor glucose closely, as clearance may be reduced. - Hepatic dysfunction: increased sensitivity to insulin may occur; adjust dosing accordingly. - Pregnancy and lactation: use only if benefits outweigh potential risks; consult a healthcare professional. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Insulin Lispro Sanofi can interact with several medications, altering its glucose‑lowering effect.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycaemia symptoms, requiring closer glucose monitoring. - Alcohol: can potentiate insulin’s effect and precipitate severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - Sulfonylureas and meglitinides: additive glucose‑lowering effect may increase hypoglycaemia risk. - Corticosteroids: may raise blood glucose, necessitating insulin dose adjustments. - Thyroid hormones: excess may enhance insulin clearance, reducing its efficacy.